NovoRapid FlexPen ranks first in fast-acting human insulin pen market

Published: 2013-08-30 06:59:00

Updated: 2013-08-30 06:59:00

Novo Nordisk’s NovoRapid FlexPen, a unique insulin pen that allows for easy injection, ranked first in the domestic fast-acting human insulin pen market during the second quarter of this year, according to IMS Health Data.

Its second-quarter market share has gained momentum, surpassing the sec...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK